Haemonetics (HAE) Q1 2027 Earnings Call Transcript
Haemonetics (HAE) reported Q1 FY2027 net revenue of $339.4 million, up 5.6% reported and 5.9% organic. Adjusted EPS was $1.14. Management raised FY2027 revenue guidance to 5% to 8% reported and 4% to 7% organic, citing momentum in Plasma and MedSurg, plus higher cash flow and debt paydown.
How this was made
The 30-second read
Why it matters
Traders can update models around FY2027 revenue growth, organic growth, and free-cash-flow conversion, while stress-testing downside from Cell Salvage capital upgrade slowing, IVT OEM weakness, and tariff-related cost offsets.
Market read
The most tradable elements are the raised FY2027 guidance ranges and the reaffirmed free-cash-flow conversion, both supported by strong operating cash flow and debt reduction, with quantified offsets from tariffs, Cell Salvage upgrade slowing, and IVT OEM decline.
What to watch
Adjusted gross margin declined 40 bps due to prior-year software license timing, and management expects the tariff refund to be largely offset by higher oil, transportation, and inflation later in the year.
Background
The article is a transcript-style summary of Haemonetics’ first quarter fiscal 2027 earnings call, including segment performance, cash flow, leverage, and updated full-year guidance.
Ticker impact
Haemonetics reported Q1 FY2027 results and raised FY2027 revenue guidance to 5% to 8% reported growth, plus raised organic guidance to 4% to 7%.
Bias toward upward repricing versus prior guidance, with volatility around whether the Cell Salvage and IVT OEM headwinds persist.
The article discloses multiple new, decision-relevant datapoints: raised reported and organic revenue guidance, reaffirmed FCF conversion, and a debt-reduction update. Offsetting negatives are also quantified (tariff refund offset, IVT OEM 5% effect, slowing Cell Salvage upgrades), which should moderate the magnitude of any reaction.
Market effects
Signals continued demand durability in plasma-derived workflows and progress in software-driven yield improvements, supportive for medtech peers tied to plasma collection and disposables.
North America plasma disposables growth (about 25%) highlights regional strength that could influence near-term channel inventory expectations.
European and Middle Eastern immunoglobulin collection mix shift (20% of global volume) suggests ongoing geographic diversification in plasma supply economics.
Counterpoint
Raised guidance may be partially offset by later-year cost pressures and equipment-cycle softness, so the market may focus on whether margins and cash conversion can sustain without the prior-year software revenue benefit.
Key entities
- companyHaemonetics
Reported Q1 FY2027 results, raised FY2027 reported and organic revenue guidance, and discussed cash conversion, debt paydown, and specific franchise headwinds.
- executiveChristopher Simon
CEO who discussed Persona PLUS adoption, VASCADE MVP XL label expansion, and IVT OEM headwinds.
- executiveJames D'Arecca
CFO who discussed margin drivers, tariff refund offset expectations, and leverage/debt paydown.
